Monique Barconey, APRN
Family · New Orleans, LANPI 1811961311
Payments from drug & device makers
Across 321 payments — averaging $27.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$1K
- Novo Nordisk$687
- Merck$667
- Lilly USA, LLC$592
- Viiv Healthcare Company$468
- plus $4K from 32 others
What the payments were for
- Food & beverage$8,68999%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 29 | $1,383 |
| AbbVie | 80 | $1,274 |
| Novo Nordisk | 22 | $687 |
| Merck | 37 | $667 |
| Lilly USA, LLC | 13 | $592 |
| Viiv Healthcare Company | 5 | $468 |
| GSK | 19 | $437 |
| Bayer | 14 | $357 |
| Amgen | 12 | $284 |
| Gilead | 5 | $271 |
| Astellas Pharma US Inc | 4 | $269 |
| Teva Pharmaceuticals USA, Inc. | 8 | $257 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $248 |
| BETA Bionics, Inc. | 1 | $216 |
| Pfizer | 9 | $183 |
| Biohaven Pharmaceuticals, Inc. | 5 | $151 |
| UCB, Inc. | 4 | $113 |
| Dexcom, Inc. | 5 | $100 |
| Corcept Therapeutics | 5 | $97 |
| Alkermes, Inc. | 3 | $88 |
| Organon | 6 | $87 |
| Axsome Therapeutics, Inc. | 3 | $63 |
| Regeneron Healthcare Solutions, Inc. | 1 | $57 |
| Sunovion Pharmaceuticals Inc. | 3 | $52 |
| Neurocrine Biosciences, Inc. | 2 | $44 |
| Corium, LLC | 2 | $42 |
| Lundbeck LLC | 2 | $38 |
| Idorsia Pharmaceuticals US Inc | 2 | $37 |
| Evofem Biosciences, Inc. | 3 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Ironwood Pharmaceuticals, Inc | 2 | $28 |
| Novartis | 1 | $22 |
| Boehringer Ingelheim | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Phadia US Inc. | 1 | $19 |
| Mylan Pharmaceuticals Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Exact Sciences | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,789 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 137 | $167,663 |
| LinzessLinaclotide | 127 | $92,785 |
| EliquisApixaban | 77 | $55,066 |
| Abilify MaintenaAripiprazole | 16 | $46,051 |
| TrulicityDulaglutide | 37 | $36,549 |
| MounjaroTirzepatide | 32 | $33,268 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $31,862 |
| FarxigaDapagliflozin Propanediol | 38 | $30,002 |
| TradjentaLinagliptin | 31 | $29,138 |
| JardianceEmpagliflozin | 24 | $27,652 |
| VraylarCariprazine Hcl | 12 | $18,372 |
| XareltoRivaroxaban | 23 | $18,280 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $14,549 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $12,465 |
| Bydureon BciseExenatide Microspheres | 14 | $11,624 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $687 | $178,651148 claims |
| AbbVieLinzess, Vraylar | $1,274 | $111,157139 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $592 | $69,81769 claims |
| Boehringer IngelheimTradjenta, Jardiance | $19 | $56,79055 claims |
| PfizerEliquis | $183 | $55,06677 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,383 | $51,76076 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $17 | $46,05116 claims |
| GSKTrelegy Ellipta | $437 | $31,86236 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.
Other family in New Orleans
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Robert ByramNew Orleans$49K
- Amy SchmittNew Orleans$48K
- Eric BabineauxNew Orleans$32K
- Cherie AlbroNew Orleans$29K
- Aimee ScroggsNew Orleans$20K
- Kelly BaquetNew Orleans$18K
- Lori LemoineNew Orleans$17K
- Jennifer GreenheckNew Orleans$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.